Large Scale Biology Corporation Announces the Issuance of Thirteen New U.S. Patents and Several New Allowances
The 13 new issuances comprise 3 patents on vectors for gene expression in plant as well as animal host systems, 2 patents on plant-based bioprocessing methods, and 2 on vaccines and methods to manufacture vaccines. Simultaneously announced was the issuance of 2 U.S. patents to LSBC on the Company's unique gene shuffling and molecular evolution technology (GRAMMR(TM)), as well as 4 more patents (3 newly issued) to LSBC's subsidiary company, Predictive Diagnostics, Inc. (PDI), on methods for biomarker discovery and diagnostics.
In addition to these issued patents, LSBC has received notice of allowance for three additional applications. Application 10/061,969, entitled "Microarrays and Their Manufacture by Slicing," describes a unique method of manufacturing microarray chips, with utility in the fields of genomics and proteomics. Application 10/280,725, entitled "Recombinant Viral Nucleic Acids," describes the application of LSBC's transient, virus-driven gene expression technology (GENEWARE®) to animal cells. Lastly, application 10/193,142, entitled "Production of a Parvovirus Vaccine in Plants as Viral Coat Protein Fusions," describes methods and compositions to produce animal health vaccines using efficient plant virus-based expression technology.
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.